المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
LibKey Link

المؤلفون: Kirton A., Benseler S.M., Brooks B.L., Gowdie P., Sheikh S., Deschamps K., Yeates K.O., Fay-McClymont T.B., Twilt M., Westmacott R., Dropol A.

مصطلحات الفهرس: childhood disease/di [Diagnosis], article, blood vessel diameter, central nervous system disease/di [Diagnosis], central nervous system disease/dt [Drug Therapy], child, childhood disease/dt [Drug Therapy], cognitive defect, controlled study, data base, disease burden, disease severity, female, functional assessment, human, intellectual impairment/di [Diagnosis], major clinical study, male, memory disorder/di [Diagnosis], multicenter study (topic), neuroimaging, neuropsychological test, nuclear magnetic resonance imaging, onset age, outcome assessment, phenotype, preschool child, priority journal, retrospective study, school child, scoring system, seizure, symptom, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], Wechsler intelligence scale for children, working memory, antibiotic agent, anticonvulsive agent, azathioprine/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], mycophenolate mofetil/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], psychotropic agent, childhood primary central nervous system vasculitis/di [Diagnosis], childhood primary central nervous system vasculitis/dt [Drug Therapy], Full Scale IQ score, Verbal Comprehension and Perceptual Reasoning index score, Working Memory and Processing Speed index score, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36142
Neuropsychology
Click here for full text options
LibKey Link

المؤلفون: Kirton A., Benseler S.M., Brooks B.L., Gowdie P., Sheikh S., Deschamps K., Yeates K.O., Fay-McClymont T.B., Twilt M., Westmacott R., Dropol A.

مصطلحات الفهرس: childhood disease/di [Diagnosis], article, blood vessel diameter, central nervous system disease/di [Diagnosis], central nervous system disease/dt [Drug Therapy], child, childhood disease/dt [Drug Therapy], cognitive defect, controlled study, data base, disease burden, disease severity, female, functional assessment, human, intellectual impairment/di [Diagnosis], major clinical study, male, memory disorder/di [Diagnosis], multicenter study (topic), neuroimaging, neuropsychological test, nuclear magnetic resonance imaging, onset age, outcome assessment, phenotype, preschool child, priority journal, retrospective study, school child, scoring system, seizure, symptom, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], Wechsler intelligence scale for children, working memory, antibiotic agent, anticonvulsive agent, azathioprine/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], mycophenolate mofetil/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], psychotropic agent, childhood primary central nervous system vasculitis/di [Diagnosis], childhood primary central nervous system vasculitis/dt [Drug Therapy], Full Scale IQ score, Verbal Comprehension and Perceptual Reasoning index score, Working Memory and Processing Speed index score, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36142
Neuropsychology
LibKey Link

المؤلفون: Antony A., Connelly K., De Silva T., Eades L., Tillett W., Morand E., Ayoub S.

مصطلحات الفهرس: psoriatic arthritis/di [Diagnosis], psoriatic arthritis/dt [Drug Therapy], rheumatic disease, rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dt [Drug Therapy], rheumatology, scleroderma/di [Diagnosis], scleroderma/dt [Drug Therapy], social acceptance, spondylarthritis/di [Diagnosis], spondylarthritis/dt [Drug Therapy], systemic lupus erythematosus/di [Diagnosis], systemic lupus erythematosus/dt [Drug Therapy], telehealth, therapeutic misconception, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], Janus kinase inhibitor/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], secukinumab/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], infection control, adult, article, controlled study, coronavirus disease 2019/di [Diagnosis], coronavirus disease 2019/dt [Drug Therapy], disease course, disease severity, drug use, female, health survey, human, major clinical study, male, medical information, middle aged, pandemic, patient participation, patient risk, perception, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29085
Arthritis Care and Research
Click here for full text options
LibKey Link

المؤلفون: Anders H.-J., Merkel P.A., Savage C.O.S., Specks U., Kain R., Jayne D.R., Lyons P.A., Gordon J., Kitching A.R., Brouwer E., Basu N., Kullman J.

مصطلحات الفهرس: infection, kidney disease, macrophage, maintenance therapy, microscopic polyangiitis, monocyte, neutrophil, nonhuman, pathogenesis, pathophysiology, prevalence, priority journal, prognosis, quality of life, respiratory tract disease, review, risk factor, screening, T lymphocyte, treatment duration, Wegener granulomatosis/dt [Drug Therapy], Wegener granulomatosis/et [Etiology], autoantigen/ec [Endogenous Compound], biological marker/ec [Endogenous Compound], cyclophosphamide/dt [Drug Therapy], glucocorticoid/dt [Drug Therapy], immunoglobulin/dt [Drug Therapy], immunomodulating agent/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], mepolizumab/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], neutrophil cytoplasmic antibody/ec [Endogenous Compound], rituximab/dt [Drug Therapy], eosinophilic granulomatosis with polyangiitis/dt [Drug Therapy], microvasculature, ANCA associated vasculitis/di [Diagnosis], ANCA associated vasculitis/dm [Disease Management], ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/ep [Epidemiology], ANCA associated vasculitis/et [Etiology], ANCA associated vasculitis/pc [Prevention], B lymphocyte, biopsy, cardiovascular disease, cellular immunity, clinical feature, clinical trial (topic), comorbidity, complement activation, diagnostic imaging, disease activity, disease association, disease classification, disease severity, environmental factor, genetics, human, incidence, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29087
Click here for full text options
LibKey Link

المؤلفون: Antony A., Connelly K., De Silva T., Eades L., Tillett W., Morand E., Ayoub S.

مصطلحات الفهرس: psoriatic arthritis/di [Diagnosis], psoriatic arthritis/dt [Drug Therapy], rheumatic disease, rheumatoid arthritis/di [Diagnosis], rheumatoid arthritis/dt [Drug Therapy], rheumatology, scleroderma/di [Diagnosis], scleroderma/dt [Drug Therapy], social acceptance, spondylarthritis/di [Diagnosis], spondylarthritis/dt [Drug Therapy], systemic lupus erythematosus/di [Diagnosis], systemic lupus erythematosus/dt [Drug Therapy], telehealth, therapeutic misconception, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], abatacept/dt [Drug Therapy], azathioprine/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], cyclosporine/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], Janus kinase inhibitor/dt [Drug Therapy], leflunomide/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], nonsteroid antiinflammatory agent/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], salazosulfapyridine/dt [Drug Therapy], secukinumab/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], tocilizumab/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], infection control, adult, article, controlled study, coronavirus disease 2019/di [Diagnosis], coronavirus disease 2019/dt [Drug Therapy], disease course, disease severity, drug use, female, health survey, human, major clinical study, male, medical information, middle aged, pandemic, patient participation, patient risk, perception, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29085
Arthritis Care and Research
LibKey Link

المؤلفون: Anders H.-J., Merkel P.A., Savage C.O.S., Specks U., Kain R., Jayne D.R., Lyons P.A., Gordon J., Kitching A.R., Brouwer E., Basu N., Kullman J.

مصطلحات الفهرس: infection, kidney disease, macrophage, maintenance therapy, microscopic polyangiitis, monocyte, neutrophil, nonhuman, pathogenesis, pathophysiology, prevalence, priority journal, prognosis, quality of life, respiratory tract disease, review, risk factor, screening, T lymphocyte, treatment duration, Wegener granulomatosis/dt [Drug Therapy], Wegener granulomatosis/et [Etiology], autoantigen/ec [Endogenous Compound], biological marker/ec [Endogenous Compound], cyclophosphamide/dt [Drug Therapy], glucocorticoid/dt [Drug Therapy], immunoglobulin/dt [Drug Therapy], immunomodulating agent/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], mepolizumab/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], neutrophil cytoplasmic antibody/ec [Endogenous Compound], rituximab/dt [Drug Therapy], eosinophilic granulomatosis with polyangiitis/dt [Drug Therapy], microvasculature, ANCA associated vasculitis/di [Diagnosis], ANCA associated vasculitis/dm [Disease Management], ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/ep [Epidemiology], ANCA associated vasculitis/et [Etiology], ANCA associated vasculitis/pc [Prevention], B lymphocyte, biopsy, cardiovascular disease, cellular immunity, clinical feature, clinical trial (topic), comorbidity, complement activation, diagnostic imaging, disease activity, disease association, disease classification, disease severity, environmental factor, genetics, human, incidence, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29087
Nature Reviews Disease Primers
LibKey Link

المؤلفون: Opat S., Casan J.M.L., Wong J., Northcott M.J.

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922
Human Vaccines and Immunotherapeutics
Click here for full text options
LibKey Link

المؤلفون: Opat S., Casan J.M.L., Wong J., Northcott M.J.

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922
Human Vaccines and Immunotherapeutics
LibKey Link

المؤلفون: Nash M., Bills H., Francis P., Heaton V.

مصطلحات الفهرس: female, fever, gait disorder, hemoglobin determination, human, human cell, human tissue, lethargy, letter, malnutrition/dt [Drug Therapy], microcytic anemia/di [Diagnosis], myositis/di [Diagnosis], myositis/dt [Drug Therapy], night sweat, priority journal, symptom, twins, vasculitis/di [Diagnosis], vasculitis/dt [Drug Therapy], vasculitis/si [Side Effect], vitamin supplementation, whole body MRI, whole body PET, celecoxib/dt [Drug Therapy], fluorodeoxyglucose, hemoglobin/ec [Endogenous Compound], minocycline/ae [Adverse Drug Reaction], minocycline/dt [Drug Therapy], vitamin D/cb [Drug Combination], vitamin D/dt [Drug Therapy], zinc/cb [Drug Combination], zinc/dt [Drug Therapy], zinc/po [Oral Drug Administration], shuffling gait, acne/dt [Drug Therapy], adolescent, anorexia, anxiety, autism, body weight loss, bone marrow biopsy, case report, clinical article, clinical examination, depression, disease severity, drug withdrawal, erythrocyte sedimentation rate, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36883
Journal of Paediatrics and Child Health
Click here for full text options
LibKey Link

المؤلفون: Kitching A.R., Gan P.-Y., O'Sullivan K.M., Ooi J.D., Alikhan M.A., Odobasic D., Summers S.A., Holdsworth S.R.

مصطلحات الفهرس: drug efficacy, drug mechanism, effector cell, female, glomerulonephritis/dt [Drug Therapy], glomerulonephritis/pc [Prevention], hematuria, human, human tissue, immunomodulation, in vitro study, injury severity, kidney biopsy, kidney cell, kidney dysfunction, kidney function, kidney injury, kidney tubule damage, lymphocyte proliferation, male, mast cell degranulation, mouse, neutrophil, nonhuman, phenotype, priority journal, proteinuria, renal protection, C reactive protein/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], cromoglycate disodium/dv [Drug Development], cromoglycate disodium/dt [Drug Therapy], cromoglycate disodium/ip [Intraperitoneal Drug Administration], cromoglycate disodium/pd [Pharmacology], gamma interferon/ec [Endogenous Compound], glomerulus basement membrane antibody, interleukin 10/ec [Endogenous Compound], interleukin 17/ec [Endogenous Compound], myeloperoxidase/ec [Endogenous Compound], neutrophil cytoplasmic antibody/ec [Endogenous Compound], macrophage, aged, albuminuria, ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/pc [Prevention], animal cell, animal experiment, animal model, animal tissue, article, autoimmunity, bone marrow derived mast cell, CD4+ T lymphocyte, cell interaction, cellular immunity, clinical article, coculture, controlled study, creatinine blood level, cytokine production, dendritic cell, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39643
Journal of the American Society of Nephrology
Click here for full text options
LibKey Link

المؤلفون: Hutton H.L., Kitching A.R., Holdsworth S.R.

مصطلحات الفهرس: glomerulonephritis, human, humoral immunity, in vitro study, in vivo study, lymphocyte differentiation, Masugi nephritis, neutrophil count, nonhuman, pathogenesis, priority journal, prospective study, regulatory T lymphocyte, remission, review, spleen cell, Staphylococcus aureus, T lymphocyte, Th1 cell, Th17 cell, Th2 cell, tissue specificity, azathioprine/ct [Clinical Trial], azathioprine/dt [Drug Therapy], CD18 antigen/ec [Endogenous Compound], complement component C5/ec [Endogenous Compound], complement component C5a/ec [Endogenous Compound], complement component C5a receptor/ec [Endogenous Compound], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/dt [Drug Therapy], gamma interferon/ec [Endogenous Compound], interleukin 17/ec [Endogenous Compound], interleukin 23/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], methotrexate/ct [Clinical Trial], methotrexate/dt [Drug Therapy], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/dt [Drug Therapy], myeloblastin/ec [Endogenous Compound], myeloperoxidase/ec [Endogenous Compound], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], MPO gene, PR3 gene, immunosuppressive treatment, ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/et [Etiology], ANCA associated vasculitis/th [Therapy], apoptosis, bone marrow transplantation, CD4+ T lymphocyte, CD8+ T lymphocyte, cytokine release, dendritic cell, disease severity, drug efficacy, gene expression, genetic risk, genome-wide association study, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38525
Seminars in Nephrology
Click here for full text options
LibKey Link

المؤلفون: Kitching A.R., Gan P.-Y., O'Sullivan K.M., Ooi J.D., Alikhan M.A., Odobasic D., Summers S.A., Holdsworth S.R.

مصطلحات الفهرس: drug efficacy, drug mechanism, effector cell, female, glomerulonephritis/dt [Drug Therapy], glomerulonephritis/pc [Prevention], hematuria, human, human tissue, immunomodulation, in vitro study, injury severity, kidney biopsy, kidney cell, kidney dysfunction, kidney function, kidney injury, kidney tubule damage, lymphocyte proliferation, male, mast cell degranulation, mouse, neutrophil, nonhuman, phenotype, priority journal, proteinuria, renal protection, C reactive protein/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], cromoglycate disodium/dv [Drug Development], cromoglycate disodium/dt [Drug Therapy], cromoglycate disodium/ip [Intraperitoneal Drug Administration], cromoglycate disodium/pd [Pharmacology], gamma interferon/ec [Endogenous Compound], glomerulus basement membrane antibody, interleukin 10/ec [Endogenous Compound], interleukin 17/ec [Endogenous Compound], myeloperoxidase/ec [Endogenous Compound], neutrophil cytoplasmic antibody/ec [Endogenous Compound], macrophage, aged, albuminuria, ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/pc [Prevention], animal cell, animal experiment, animal model, animal tissue, article, autoimmunity, bone marrow derived mast cell, CD4+ T lymphocyte, cell interaction, cellular immunity, clinical article, coculture, controlled study, creatinine blood level, cytokine production, dendritic cell, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39643
Journal of the American Society of Nephrology
Click here for full text options
LibKey Link

المؤلفون: Hutton H.L., Kitching A.R., Holdsworth S.R.

مصطلحات الفهرس: glomerulonephritis, human, humoral immunity, in vitro study, in vivo study, lymphocyte differentiation, Masugi nephritis, neutrophil count, nonhuman, pathogenesis, priority journal, prospective study, regulatory T lymphocyte, remission, review, spleen cell, Staphylococcus aureus, T lymphocyte, Th1 cell, Th17 cell, Th2 cell, tissue specificity, azathioprine/ct [Clinical Trial], azathioprine/dt [Drug Therapy], CD18 antigen/ec [Endogenous Compound], complement component C5/ec [Endogenous Compound], complement component C5a/ec [Endogenous Compound], complement component C5a receptor/ec [Endogenous Compound], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/dt [Drug Therapy], gamma interferon/ec [Endogenous Compound], interleukin 17/ec [Endogenous Compound], interleukin 23/ec [Endogenous Compound], interleukin 8/ec [Endogenous Compound], methotrexate/ct [Clinical Trial], methotrexate/dt [Drug Therapy], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/dt [Drug Therapy], myeloblastin/ec [Endogenous Compound], myeloperoxidase/ec [Endogenous Compound], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], MPO gene, PR3 gene, immunosuppressive treatment, ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/et [Etiology], ANCA associated vasculitis/th [Therapy], apoptosis, bone marrow transplantation, CD4+ T lymphocyte, CD8+ T lymphocyte, cytokine release, dendritic cell, disease severity, drug efficacy, gene expression, genetic risk, genome-wide association study, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38525
Seminars in Nephrology
Click here for full text options
LibKey Link

المؤلفون: Ghali J.R., Kitching A.R., Holdsworth S.R., Wang Y.M.

مصطلحات الفهرس: drug efficacy, drug response, gene, glomerulonephritis/et [Etiology], human, humoral immunity, immune response, immunological tolerance, immunoregulation, innate immunity, lymphocyte count, lymphocyte proliferation, nonhuman, pathogenesis, priority journal, protein expression, proteinuria/dt [Drug Therapy], proteinuria/et [Etiology], regulatory T lymphocyte, systemic lupus erythematosus/dt [Drug Therapy], systemic lupus erythematosus/et [Etiology], upregulation, cyclophosphamide/dt [Drug Therapy], cytotoxic T lymphocyte antigen 4/ec [Endogenous Compound], gamma interferon/ec [Endogenous Compound], glucocorticoid/dt [Drug Therapy], immunoglobulin G/ec [Endogenous Compound], interleukin 10/dt [Drug Therapy], interleukin 10/ec [Endogenous Compound], interleukin 2/ct [Clinical Trial], interleukin 2/dt [Drug Therapy], rituximab/dt [Drug Therapy], STAT3 protein/ec [Endogenous Compound], FOXP3 gene, protein depletion, acute kidney failure/dt [Drug Therapy], acute kidney failure/et [Etiology], ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/et [Etiology], antigen expression, apoptosis, article, autoimmunity, CD25+ T lymphocyte, CD4+ T lymphocyte, CD8+ T lymphocyte, cell infiltration, cell therapy, cytokine production, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39912
Nephrology
Click here for full text options
LibKey Link

المؤلفون: Ghali J.R., Kitching A.R., Holdsworth S.R., Wang Y.M.

مصطلحات الفهرس: drug efficacy, drug response, gene, glomerulonephritis/et [Etiology], human, humoral immunity, immune response, immunological tolerance, immunoregulation, innate immunity, lymphocyte count, lymphocyte proliferation, nonhuman, pathogenesis, priority journal, protein expression, proteinuria/dt [Drug Therapy], proteinuria/et [Etiology], regulatory T lymphocyte, systemic lupus erythematosus/dt [Drug Therapy], systemic lupus erythematosus/et [Etiology], upregulation, cyclophosphamide/dt [Drug Therapy], cytotoxic T lymphocyte antigen 4/ec [Endogenous Compound], gamma interferon/ec [Endogenous Compound], glucocorticoid/dt [Drug Therapy], immunoglobulin G/ec [Endogenous Compound], interleukin 10/dt [Drug Therapy], interleukin 10/ec [Endogenous Compound], interleukin 2/ct [Clinical Trial], interleukin 2/dt [Drug Therapy], rituximab/dt [Drug Therapy], STAT3 protein/ec [Endogenous Compound], FOXP3 gene, protein depletion, acute kidney failure/dt [Drug Therapy], acute kidney failure/et [Etiology], ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/et [Etiology], antigen expression, apoptosis, article, autoimmunity, CD25+ T lymphocyte, CD4+ T lymphocyte, CD8+ T lymphocyte, cell infiltration, cell therapy, cytokine production, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39912
Nephrology
LibKey Link

المؤلفون: Mateevici C., Lin B., Chandra R.V., Chong V.H.T., Fok A.

مصطلحات الفهرس: meningoencephalitis/dt [Drug Therapy], middle aged, myalgia, nasopharyngeal aspiration, neutrophilia, nonhuman, nuclear magnetic resonance imaging, polymerase chain reaction, rhinorrhea, sinus tachycardia, thorax radiography, virus pneumonia, aciclovir/dt [Drug Therapy], C reactive protein/ec [Endogenous Compound], ceftriaxone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], penicillin G/dt [Drug Therapy], vancomycin/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], adult, allergic encephalitis/dt [Drug Therapy], article, Australia, brain vasculitis/dt [Drug Therapy], case report, cerebrospinal fluid analysis, coughing, disease association, dyspnea, electrocardiography, electroencephalography, Glasgow coma scale, human, Human metapneumovirus infection, male, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40656
Emerging Infectious Diseases
LibKey Link

المؤلفون: Chadban S.J., Atkins R.C.

مصطلحات الفهرس: glomerulonephritis/dt [Drug Therapy], glomerulonephritis/ep [Epidemiology], glomerulonephritis/et [Etiology], glomerulonephritis/su [Surgery], glomerulonephritis/th [Therapy], glomerulosclerosis/dt [Drug Therapy], glomerulus filtration rate, Goodpasture syndrome/th [Therapy], hematuria, Heymann nephritis, human, hyperlipidemia/dt [Drug Therapy], immune system, immunoglobulin A nephropathy/dt [Drug Therapy], immunosuppressive treatment, infection/si [Side Effect], infection risk, infection sensitivity, inflammation, kidney biopsy, kidney cell, kidney disease, kidney failure/dt [Drug Therapy], cyclophosphamide/po [Oral Drug Administration], kidney transplantation, leukocyte, lung hemorrhage, lupus erythematosus nephritis/dt [Drug Therapy], membranoproliferative glomerulonephritis/dt [Drug Therapy], membranous glomerulonephritis/dt [Drug Therapy], minimal change glomerulonephritis/dt [Drug Therapy], nephrotic syndrome, nonhuman, pathogenesis, plasmapheresis, priority journal, protein restriction, proteinuria/si [Side Effect], rapidly progressive glomerulonephritis/dt [Drug Therapy], rapidly progressive glomerulonephritis/th [Therapy], risk assessment, sex ratio, side effect/si [Side Effect], T cell depletion, treatment outcome, vasculitis/dt [Drug Therapy], angiotensin receptor antagonist/dt [Drug Therapy], antibody/dt [Drug Therapy], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], hirudin/dt [Drug Therapy], hirudin/pd [Pharmacology], imatinib/dt [Drug Therapy], imatinib/pd [Pharmacology], immunosuppressive agent/ae [Adverse Drug Reaction], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/iv [Intravenous Drug Administration], antibody/pd [Pharmacology], antilipemic agent/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], azathioprine/pd [Pharmacology], CD20 antibody/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], chlorambucil/pd [Pharmacology], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], immunosuppressive agent/po [Oral Drug Administration], immunosuppressive agent/pd [Pharmacology], intercellular adhesion molecule 1 antibody/dt [Drug Therapy], intercellular adhesion molecule 1 antibody/pd [Pharmacology], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/pd [Pharmacology], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/pd [Pharmacology], n(g) nitroarginine methyl ester/dt [Drug Therapy], n(g) nitroarginine methyl ester/pd [Pharmacology], nitric oxide synthase inhibitor/dt [Drug Therapy], nitric oxide synthase inhibitor/pd [Pharmacology], oligonucleotide/dt [Drug Therapy], oligonucleotide/pd [Pharmacology], prednisone/do [Drug Dose], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rapamycin/ae [Adverse Drug Reaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], steroid/dt [Drug Therapy], thrombin inhibitor/dt [Drug Therapy], thrombin inhibitor/pd [Pharmacology], unclassified drug, colony stimulating factor receptor antibody/dt [Drug Therapy], colony stimulating factor receptor antibody/pd [Pharmacology], monocyte chemotactic protein 1 antibody/dt [Drug Therapy], monocyte chemotactic protein 1 antibody/pd [Pharmacology], kidney failure/pc [Prevention], cyclophosphamide/pd [Pharmacology], cyclosporin/dt [Drug Therapy], acute kidney failure/si [Side Effect], Alport syndrome, antibody dependent cellular cytotoxicity, blood clotting, cancer susceptibility, cellular immunity, chronic glomerulonephritis, complement system, conference paper, diagnostic procedure, disease association, drug efficacy, drug induced cancer/si [Side Effect], drug safety, Conference Paper

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27330
The Lancet
Click here for full text options
LibKey Link

المؤلفون: Chadban S.J., Atkins R.C.

مصطلحات الفهرس: glomerulonephritis/dt [Drug Therapy], glomerulonephritis/ep [Epidemiology], glomerulonephritis/et [Etiology], glomerulonephritis/su [Surgery], glomerulonephritis/th [Therapy], glomerulosclerosis/dt [Drug Therapy], glomerulus filtration rate, Goodpasture syndrome/th [Therapy], hematuria, Heymann nephritis, human, hyperlipidemia/dt [Drug Therapy], immune system, immunoglobulin A nephropathy/dt [Drug Therapy], immunosuppressive treatment, infection/si [Side Effect], infection risk, infection sensitivity, inflammation, kidney biopsy, kidney cell, kidney disease, kidney failure/dt [Drug Therapy], cyclophosphamide/po [Oral Drug Administration], kidney transplantation, leukocyte, lung hemorrhage, lupus erythematosus nephritis/dt [Drug Therapy], membranoproliferative glomerulonephritis/dt [Drug Therapy], membranous glomerulonephritis/dt [Drug Therapy], minimal change glomerulonephritis/dt [Drug Therapy], nephrotic syndrome, nonhuman, pathogenesis, plasmapheresis, priority journal, protein restriction, proteinuria/si [Side Effect], rapidly progressive glomerulonephritis/dt [Drug Therapy], rapidly progressive glomerulonephritis/th [Therapy], risk assessment, sex ratio, side effect/si [Side Effect], T cell depletion, treatment outcome, vasculitis/dt [Drug Therapy], angiotensin receptor antagonist/dt [Drug Therapy], antibody/dt [Drug Therapy], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], hirudin/dt [Drug Therapy], hirudin/pd [Pharmacology], imatinib/dt [Drug Therapy], imatinib/pd [Pharmacology], immunosuppressive agent/ae [Adverse Drug Reaction], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/iv [Intravenous Drug Administration], antibody/pd [Pharmacology], antilipemic agent/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], azathioprine/pd [Pharmacology], CD20 antibody/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], chlorambucil/pd [Pharmacology], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], immunosuppressive agent/po [Oral Drug Administration], immunosuppressive agent/pd [Pharmacology], intercellular adhesion molecule 1 antibody/dt [Drug Therapy], intercellular adhesion molecule 1 antibody/pd [Pharmacology], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/pd [Pharmacology], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/pd [Pharmacology], n(g) nitroarginine methyl ester/dt [Drug Therapy], n(g) nitroarginine methyl ester/pd [Pharmacology], nitric oxide synthase inhibitor/dt [Drug Therapy], nitric oxide synthase inhibitor/pd [Pharmacology], oligonucleotide/dt [Drug Therapy], oligonucleotide/pd [Pharmacology], prednisone/do [Drug Dose], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rapamycin/ae [Adverse Drug Reaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], steroid/dt [Drug Therapy], thrombin inhibitor/dt [Drug Therapy], thrombin inhibitor/pd [Pharmacology], unclassified drug, colony stimulating factor receptor antibody/dt [Drug Therapy], colony stimulating factor receptor antibody/pd [Pharmacology], monocyte chemotactic protein 1 antibody/dt [Drug Therapy], monocyte chemotactic protein 1 antibody/pd [Pharmacology], kidney failure/pc [Prevention], cyclophosphamide/pd [Pharmacology], cyclosporin/dt [Drug Therapy], acute kidney failure/si [Side Effect], Alport syndrome, antibody dependent cellular cytotoxicity, blood clotting, cancer susceptibility, cellular immunity, chronic glomerulonephritis, complement system, conference paper, diagnostic procedure, disease association, drug efficacy, drug induced cancer/si [Side Effect], drug safety, Conference Paper

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27330
The Lancet
LibKey Link